Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
|---|---|---|---|---|---|
| DK1-C52H7 | Cynomolgus | Cynomolgus DLK1 / FA1 Protein, His Tag |  |
|
|
| DK1-H52H3 | Human | Human DLK1 / FA1 Protein, His Tag (MALS verified) |  |
|
Immobilized Human DLK1, His Tag (Cat. No. DK1-H52H3) at 1 μg/mL (100 μL/well) can bind anti DLK-1 antibody with a linear range of 0.078-5 μg/mL (QC tested).
The purity of Human DLK1, His Tag (Cat. No. DK1-H52H3) is more than 90% and the molecular weight of this protein is around 34-51 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tozinameran | BNT162b2; PF-07302048; BNT-161b1; BNT162; Bnt-162b2; BNT162b2SA; BNT-162b5 | Approved | Pfizer Inc, Biontech Se | 復必泰, Comirnaty, 复必泰 | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Biontech Se | 2020-12-02 | Infections; Anaphylaxis; Coronavirus Disease 2019 (COVID-19); Neoplasms; Severe Acute Respiratory Syndrome; Coronavirus Infections; Influenza, Human; Coronaviridae Infections | Details |
| Recombinant novel coronavirus vaccine (adenovirus type 5 vector) (CanSinoBio) | Approved | Tianjin Cansino Biotechnology Inc, Chinese Academy Of Military Medical Sciences | 克威莎, Convidecia, Convidecia Air | Mainland China | Coronavirus Disease 2019 (COVID-19) | Tianjin Cansino Biotechnology Inc | 2021-02-25 | Coronavirus Disease 2019 (COVID-19) | Details | |
| Gam-COVID-Vac | Approved | Gamaleya Research Institute Of Epidemiology And Microbiology, Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation | Sputnik V | Russian Federation | Coronavirus Disease 2019 (COVID-19) | Gamaleya Research Institute Of Epidemiology And Microbiology | 2020-08-11 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details | |
| Casirivimab/imdevimab | REGN-10933+REGN-10987; RG-6413+RG6412; REGEN-COV-2; REGN-COV2; REGN-COV-2; REGEN-COV | Approved | F. Hoffmann-La Roche Ltd | ロナプリーブ, REGEN-COV, RONAPREVE | Japan | Coronavirus Disease 2019 (COVID-19) | Chugai Pharmaceutical Co Ltd | 2021-07-19 | Coronavirus Disease 2019 (COVID-19); Rejection of organ transplantation; Coronavirus Infections; Chronic Disease | Details |
| Amubarvimab/Romlusevimab | BRII-196/BRII-198 | Approved | Tsinghua University, Shenzhen Third People'S Hospital, Brii Biosciences (Beijing) Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Tengsheng Huachuang Medical Technology (Beijing) Co Ltd | 2021-12-08 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details | |
| Tixagevimab/Cilgavimab | AZD-7442; AZD7442 | Approved | Vanderbilt University Medical Center | Evusheld, 恩适得 | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Astrazeneca Uk Ltd | 2022-03-16 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Coronaviridae Infections; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Sotrovimab | VIR-7831; GSK-4182136 | Approved | Vir Biotechnology Inc | Xevudy | Australia | Coronavirus Disease 2019 (COVID-19) | Vir Biotechnology Inc | 2021-08-23 | Hematologic Neoplasms; Solid tumours; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections; Lymphoma | Details |
| Regdanvimab | CT-P59 | Approved | Celltrion Inc | Regkirona | South Korea | Coronavirus Disease 2019 (COVID-19) | Celltrion Inc | 2021-09-18 | Coronavirus Disease 2019 (COVID-19) | Details |
| Recombinant SARS-CoV-2 vaccine (CHO Cell) (Zhifei Longcom Biopharmaceutical) | ZF2001 | Approved | Anhui Zhifei Longcom Biopharmaceutical Co Ltd, Institute Of Microbiology Of Chinese Academy Of Sciences | 智克威得 | Uzbekistan | Coronavirus Disease 2019 (COVID-19) | Anhui Zhifei Longcom Biopharmaceutical Co Ltd | 2021-03-01 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| Tozinameran | BNT162b2; PF-07302048; BNT-161b1; BNT162; Bnt-162b2; BNT162b2SA; BNT-162b5 | Approved | Pfizer Inc, Biontech Se | 復必泰, Comirnaty, 复必泰 | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Biontech Se | 2020-12-02 | Infections; Anaphylaxis; Coronavirus Disease 2019 (COVID-19); Neoplasms; Severe Acute Respiratory Syndrome; Coronavirus Infections; Influenza, Human; Coronaviridae Infections | Details |
| Recombinant novel coronavirus vaccine (adenovirus type 5 vector) (CanSinoBio) | Approved | Tianjin Cansino Biotechnology Inc, Chinese Academy Of Military Medical Sciences | 克威莎, Convidecia, Convidecia Air | Mainland China | Coronavirus Disease 2019 (COVID-19) | Tianjin Cansino Biotechnology Inc | 2021-02-25 | Coronavirus Disease 2019 (COVID-19) | Details | |
| Gam-COVID-Vac | Approved | Gamaleya Research Institute Of Epidemiology And Microbiology, Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation | Sputnik V | Russian Federation | Coronavirus Disease 2019 (COVID-19) | Gamaleya Research Institute Of Epidemiology And Microbiology | 2020-08-11 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details | |
| Casirivimab/imdevimab | REGN-10933+REGN-10987; RG-6413+RG6412; REGEN-COV-2; REGN-COV2; REGN-COV-2; REGEN-COV | Approved | F. Hoffmann-La Roche Ltd | ロナプリーブ, REGEN-COV, RONAPREVE | Japan | Coronavirus Disease 2019 (COVID-19) | Chugai Pharmaceutical Co Ltd | 2021-07-19 | Coronavirus Disease 2019 (COVID-19); Rejection of organ transplantation; Coronavirus Infections; Chronic Disease | Details |
| Amubarvimab/Romlusevimab | BRII-196/BRII-198 | Approved | Tsinghua University, Shenzhen Third People'S Hospital, Brii Biosciences (Beijing) Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Tengsheng Huachuang Medical Technology (Beijing) Co Ltd | 2021-12-08 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details | |
| Tixagevimab/Cilgavimab | AZD-7442; AZD7442 | Approved | Vanderbilt University Medical Center | Evusheld, 恩适得 | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Astrazeneca Uk Ltd | 2022-03-16 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Coronaviridae Infections; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Sotrovimab | VIR-7831; GSK-4182136 | Approved | Vir Biotechnology Inc | Xevudy | Australia | Coronavirus Disease 2019 (COVID-19) | Vir Biotechnology Inc | 2021-08-23 | Hematologic Neoplasms; Solid tumours; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections; Lymphoma | Details |
| Regdanvimab | CT-P59 | Approved | Celltrion Inc | Regkirona | South Korea | Coronavirus Disease 2019 (COVID-19) | Celltrion Inc | 2021-09-18 | Coronavirus Disease 2019 (COVID-19) | Details |
| Recombinant SARS-CoV-2 vaccine (CHO Cell) (Zhifei Longcom Biopharmaceutical) | ZF2001 | Approved | Anhui Zhifei Longcom Biopharmaceutical Co Ltd, Institute Of Microbiology Of Chinese Academy Of Sciences | 智克威得 | Uzbekistan | Coronavirus Disease 2019 (COVID-19) | Anhui Zhifei Longcom Biopharmaceutical Co Ltd | 2021-03-01 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Bamlanivimab | LY-3819253 | Phase 3 Clinical | AbCellera Biologics Inc, Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| mRNA-1273.231 | mRNA-1273.231 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| mRNA-1273.815 | mRNA-1273.815 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Riltozinameran | Phase 3 Clinical | Biontech Se, Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details | |
| pemivibart | VYD222; VYD-222 | Phase 3 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | |
| abdavomeran | BNT162b1 | Phase 3 Clinical | Biontech Se | Respiratory Tract Infections; RNA Virus Infections; Drug-Related Side Effects and Adverse Reactions; Virus Diseases; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| GSK-4362620A | GSK-4362620A | Phase 3 Clinical | Medicago Inc, Gsk Vaccines Gmbh | Coronavirus Disease 2019 (COVID-19) | Details |
| Ogalvibart/Crexavibart | BMS-986414 + BMS-986413 | Phase 3 Clinical | The Rockefeller University, Bristol Myers Squibb Srlcompany | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| Imdevimab | RG-6412 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Simaravibart | MAD-0004J08 | Phase 3 Clinical | Fondazione Toscana Life Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
| ABP-300 | ABP-300; MW-05(Mabwell/Abpro) | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd, Abpro Corp | Coronavirus Disease 2019 (COVID-19) | Details |
| Ensovibep | MP-0420 | Phase 3 Clinical | Molecular Partners Ag | Coronavirus Disease 2019 (COVID-19) | Details |
| PTX-COVID19-B | Phase 3 Clinical | Providence Therapeutics Holdings Inc | Coronavirus Disease 2019 (COVID-19) | Details | |
| Amubarvimab | BRII-196; BRII196 | Phase 3 Clinical | Brii Biosciences (Beijing) Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Romlusevimab | BRII198; BRII-198 | Phase 3 Clinical | Brii Biosciences (Beijing) Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Upanovimab | HB-27; SCTA-01 | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| STI-2099 | STI-2099 | Phase 2 Clinical | Sorrento Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| SA-55 | SA55; SA-55; BD55-5514 | Phase 2 Clinical | Sinovac Biotech Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Reluscovtogene ralaplasmid | INO-4800; INO4800; PGX-9501 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Hepatitis B | Details |
| SARS-CoV-2 mRNA Vaccine(Argorna) | RBMRNA-176 | Phase 2 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Sipavibart | AZD-3152; AZD3152 | Phase 2 Clinical | Astrazeneca Plc | Coronavirus Disease 2019 (COVID-19) | Details |
| Recombinant SARS-CoV-2 Vaccine（variant）（Shanghai Zerun） | Phase 2 Clinical | Shanghai Zerun Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
| HY-3000 | HY-3000 | Phase 2 Clinical | Hybio Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Betuvax-CoV-2 | Phase 2 Clinical | Human Stem Cells Institute, Russia | Coronavirus Disease 2019 (COVID-19) | Details | |
| FBR-002 | FBR-002 | Phase 2 Clinical | Fabentech | Coronavirus Disease 2019 (COVID-19) | Details |
| IBIO123 | IBIO-123 | Phase 2 Clinical | Immune Biosolutions Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Bebtelovimab | LY-CoV1404 monoclonal antibody; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404 | Phase 2 Clinical | Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19) | Details |
| AKS-452-X | AKS-452-X; AKS-452X | Phase 2 Clinical | Akston Biosciences Corp | Coronavirus Disease 2019 (COVID-19) | Details |
| Casirivimab | RG-6413 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| LY-CovMab | LY-CovMab | Phase 2 Clinical | Luye Pharma Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| COR-101 | STE90-C11 | Phase 2 Clinical | Corat Therapeutics Gmbh | Coronavirus Disease 2019 (COVID-19) | Details |
| GLS-5310 | GLS-5310 | Phase 2 Clinical | Geneone Life Science Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| BGB-DXP604 | DXP-604 | Phase 2 Clinical | Beigene Ltd, Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Lomtegovimab | BI-767551 | Phase 2 Clinical | German Center For Infection Research, University Of Cologne | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social) | Phase 2 Clinical | Universidad De Costa Rica | Coronavirus Disease 2019 (COVID-19) | Details | |
| ChulaCov19 mRNA vaccine | Phase 2 Clinical | Chulalongkorn University | Coronavirus Disease 2019 (COVID-19) | Details | |
| MW-33 | MW-33; 9MW3311; 9-MW3311; 9MW-3311; 9-MW-3311 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| DXP-593 | BGB DXP593; DXP-593 | Phase 2 Clinical | Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Etesevimab | LY-3832479; LY-CoV016; JS-016 | Phase 2 Clinical | Institute Of Microbiology Of Chinese Academy Of Sciences, Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome | Details |
| AVACC-10 | AVACC-10 | Phase 1 Clinical | Intravacc | Coronavirus Disease 2019 (COVID-19) | Details |
| BAT-2022 | BAT-2022 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| SCB-2020S | SCB-2020S | Phase 1 Clinical | Clover Biopharmaceuticals Aus Pty Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| IN-006 | IN-006 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| IMM-BCP-01 | IMM-BCP-01 | Phase 1 Clinical | Immunome Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| RBMRNA-405 | RBMRNA-405 | Phase 1 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| GB-0669 | GB-0669 | Phase 1 Clinical | Generate Biomedicines Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| PA-001(PeptiDream) | Phase 1 Clinical | Peptidream | Coronavirus Disease 2019 (COVID-19) | Details | |
| REGN17092 | REGN-17092; REGN17092 | Phase 1 Clinical | Details | ||
| B/HPIV3/S-6P | B/HPIV-3/S-6-P | Phase 1 Clinical | National Institutes Of Health | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| F-61 | F-61 | Phase 1 Clinical | Wuhan Institute Of Biological Products Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-918 | GRT-R918; GRT-R-918 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-914 | GRT-R914; GRT-R-914 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-912 | GRT-R912; GRT-R-912 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| MTx-COVAB36 | MTx-COVAB36 | Phase 1 Clinical | Memo Therapeutics AG | Coronavirus Disease 2019 (COVID-19) | Details |
| Gorivitug | REGN-15160 | Phase 1 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | |
| SI-F019 | SI-F019; F-019; SZ-F019 | Phase 1 Clinical | Details | ||
| CG-SpikeDown | Phase 1 Clinical | Caregen Co Ltd | Details | ||
| CT-P63 | CT-P-63; CT-P63 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| JS-026 | JS-026 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| ChAd-triCoV | ChAd-triCoV | Phase 1 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| Ad5-triCoV/Mac | Ad5-triCoV/Mac | Phase 1 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| JMB-2002 | JMB-2002 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Ogalvibart | BMS-986414 | Phase 1 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19) | Details |
| Crexavibart | C144-LS; C144LS; BMS-986413 | Phase 1 Clinical | The Rockefeller University, Bristol Myers Squibb Srlcompany | Coronavirus Disease 2019 (COVID-19) | Details |
| ABBV-47D11 | HBM9022; ABBV-47D11; HBM-9022; 47D11 | Phase 1 Clinical | Abbvie Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Enuzovimab | HFB-3013; HFB30132A | Phase 1 Clinical | HiFiBiO Therapeutics | Coronavirus Disease 2019 (COVID-19) | Details |
| ADM-03820 | Phase 1 Clinical | Ology Bioservices Inc | Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome | Details | |
| HLX-71 | HLX-71 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Anti-SARS-CoV-2 IgY (Stanford University) | Phase 1 Clinical | Stanford University | Coronavirus Disease 2019 (COVID-19) | Details | |
| Bamlanivimab | LY-3819253 | Phase 3 Clinical | AbCellera Biologics Inc, Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| mRNA-1273.231 | mRNA-1273.231 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| mRNA-1273.815 | mRNA-1273.815 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Riltozinameran | Phase 3 Clinical | Biontech Se, Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details | |
| pemivibart | VYD222; VYD-222 | Phase 3 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | |
| abdavomeran | BNT162b1 | Phase 3 Clinical | Biontech Se | Respiratory Tract Infections; RNA Virus Infections; Drug-Related Side Effects and Adverse Reactions; Virus Diseases; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| GSK-4362620A | GSK-4362620A | Phase 3 Clinical | Medicago Inc, Gsk Vaccines Gmbh | Coronavirus Disease 2019 (COVID-19) | Details |
| Ogalvibart/Crexavibart | BMS-986414 + BMS-986413 | Phase 3 Clinical | The Rockefeller University, Bristol Myers Squibb Srlcompany | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | Details |
| Imdevimab | RG-6412 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Simaravibart | MAD-0004J08 | Phase 3 Clinical | Fondazione Toscana Life Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
| ABP-300 | ABP-300; MW-05(Mabwell/Abpro) | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd, Abpro Corp | Coronavirus Disease 2019 (COVID-19) | Details |
| Ensovibep | MP-0420 | Phase 3 Clinical | Molecular Partners Ag | Coronavirus Disease 2019 (COVID-19) | Details |
| PTX-COVID19-B | Phase 3 Clinical | Providence Therapeutics Holdings Inc | Coronavirus Disease 2019 (COVID-19) | Details | |
| Amubarvimab | BRII-196; BRII196 | Phase 3 Clinical | Brii Biosciences (Beijing) Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Romlusevimab | BRII198; BRII-198 | Phase 3 Clinical | Brii Biosciences (Beijing) Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Upanovimab | HB-27; SCTA-01 | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| STI-2099 | STI-2099 | Phase 2 Clinical | Sorrento Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| SA-55 | SA55; SA-55; BD55-5514 | Phase 2 Clinical | Sinovac Biotech Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Reluscovtogene ralaplasmid | INO-4800; INO4800; PGX-9501 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Hepatitis B | Details |
| SARS-CoV-2 mRNA Vaccine(Argorna) | RBMRNA-176 | Phase 2 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Sipavibart | AZD-3152; AZD3152 | Phase 2 Clinical | Astrazeneca Plc | Coronavirus Disease 2019 (COVID-19) | Details |
| Recombinant SARS-CoV-2 Vaccine（variant）（Shanghai Zerun） | Phase 2 Clinical | Shanghai Zerun Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
| HY-3000 | HY-3000 | Phase 2 Clinical | Hybio Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Betuvax-CoV-2 | Phase 2 Clinical | Human Stem Cells Institute, Russia | Coronavirus Disease 2019 (COVID-19) | Details | |
| FBR-002 | FBR-002 | Phase 2 Clinical | Fabentech | Coronavirus Disease 2019 (COVID-19) | Details |
| IBIO123 | IBIO-123 | Phase 2 Clinical | Immune Biosolutions Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Bebtelovimab | LY-CoV1404 monoclonal antibody; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404 | Phase 2 Clinical | Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19) | Details |
| AKS-452-X | AKS-452-X; AKS-452X | Phase 2 Clinical | Akston Biosciences Corp | Coronavirus Disease 2019 (COVID-19) | Details |
| Casirivimab | RG-6413 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| LY-CovMab | LY-CovMab | Phase 2 Clinical | Luye Pharma Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| COR-101 | STE90-C11 | Phase 2 Clinical | Corat Therapeutics Gmbh | Coronavirus Disease 2019 (COVID-19) | Details |
| GLS-5310 | GLS-5310 | Phase 2 Clinical | Geneone Life Science Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| BGB-DXP604 | DXP-604 | Phase 2 Clinical | Beigene Ltd, Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Lomtegovimab | BI-767551 | Phase 2 Clinical | German Center For Infection Research, University Of Cologne | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social) | Phase 2 Clinical | Universidad De Costa Rica | Coronavirus Disease 2019 (COVID-19) | Details | |
| ChulaCov19 mRNA vaccine | Phase 2 Clinical | Chulalongkorn University | Coronavirus Disease 2019 (COVID-19) | Details | |
| MW-33 | MW-33; 9MW3311; 9-MW3311; 9MW-3311; 9-MW-3311 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| DXP-593 | BGB DXP593; DXP-593 | Phase 2 Clinical | Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Etesevimab | LY-3832479; LY-CoV016; JS-016 | Phase 2 Clinical | Institute Of Microbiology Of Chinese Academy Of Sciences, Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome | Details |
| AVACC-10 | AVACC-10 | Phase 1 Clinical | Intravacc | Coronavirus Disease 2019 (COVID-19) | Details |
| BAT-2022 | BAT-2022 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| SCB-2020S | SCB-2020S | Phase 1 Clinical | Clover Biopharmaceuticals Aus Pty Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| IN-006 | IN-006 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| IMM-BCP-01 | IMM-BCP-01 | Phase 1 Clinical | Immunome Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| RBMRNA-405 | RBMRNA-405 | Phase 1 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| GB-0669 | GB-0669 | Phase 1 Clinical | Generate Biomedicines Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| PA-001(PeptiDream) | Phase 1 Clinical | Peptidream | Coronavirus Disease 2019 (COVID-19) | Details | |
| REGN17092 | REGN-17092; REGN17092 | Phase 1 Clinical | Details | ||
| B/HPIV3/S-6P | B/HPIV-3/S-6-P | Phase 1 Clinical | National Institutes Of Health | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| F-61 | F-61 | Phase 1 Clinical | Wuhan Institute Of Biological Products Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-918 | GRT-R918; GRT-R-918 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-914 | GRT-R914; GRT-R-914 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| GRT-R-912 | GRT-R912; GRT-R-912 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| MTx-COVAB36 | MTx-COVAB36 | Phase 1 Clinical | Memo Therapeutics AG | Coronavirus Disease 2019 (COVID-19) | Details |
| Gorivitug | REGN-15160 | Phase 1 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | |
| SI-F019 | SI-F019; F-019; SZ-F019 | Phase 1 Clinical | Details | ||
| CG-SpikeDown | Phase 1 Clinical | Caregen Co Ltd | Details | ||
| CT-P63 | CT-P-63; CT-P63 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| JS-026 | JS-026 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| ChAd-triCoV | ChAd-triCoV | Phase 1 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| Ad5-triCoV/Mac | Ad5-triCoV/Mac | Phase 1 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections | Details |
| JMB-2002 | JMB-2002 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Ogalvibart | BMS-986414 | Phase 1 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19) | Details |
| Crexavibart | C144-LS; C144LS; BMS-986413 | Phase 1 Clinical | The Rockefeller University, Bristol Myers Squibb Srlcompany | Coronavirus Disease 2019 (COVID-19) | Details |
| ABBV-47D11 | HBM9022; ABBV-47D11; HBM-9022; 47D11 | Phase 1 Clinical | Abbvie Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Enuzovimab | HFB-3013; HFB30132A | Phase 1 Clinical | HiFiBiO Therapeutics | Coronavirus Disease 2019 (COVID-19) | Details |
| ADM-03820 | Phase 1 Clinical | Ology Bioservices Inc | Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome | Details | |
| HLX-71 | HLX-71 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Anti-SARS-CoV-2 IgY (Stanford University) | Phase 1 Clinical | Stanford University | Coronavirus Disease 2019 (COVID-19) | Details |
This web search service is supported by Google Inc.
A-Z
